Pharmaids Pharmaceuticals Complete Financial Statements
In FY2025, Pharmaids Pharmaceuticals (PHARMAID) reported revenue ₹12 Cr, net profit ₹-3 Cr and EPS ₹-0.70, with a net profit margin of -25.0% and ROE of -5.5%. Full financial statements from FY2022 to FY2025 (4 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. For live price, earnings ratios and company overview, see Pharmaids Pharmaceuticals share price screener.
Complete Financial Data Export
Profitability Ratios
Balance Sheet Ratios
PHARMAID Revenue, Net Profit & EBITDA — Year-on-Year Growth
PHARMAID YoY (Sept 2024 vs Sept 2025) — revenue +140.0%, net profit -50.0%, expenses +75.0%. Explore PHARMAID intrinsic value to estimate fundamental worth using multiple valuation models.
PHARMAID Income Statement — Revenue, EBITDA & Net Profit
Pharmaids Pharmaceuticals revenue ₹12 Cr, EBITDA ₹-2 Cr, net profit ₹-3 Cr, EPS ₹-0.70 (2025) — net profit margin -25.0%. Review PHARMAID P/E ratio to evaluate earnings-based valuation against sector peers.
| Particulars | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | Sept 2024 | Mar 2024 | Jun 2024 | Dec 2024 | Sept 2023 | Mar 2023 | Jun 2023 | Jun 2023 | Dec 2023 | Sept 2022 | Jun 2022 | Dec 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 12 | 5 | 7 | 6 | 5 | 6 | 5 | 5 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Expenses | 14 | 9 | 12 | 8 | 8 | 11 | 8 | 8 | 1 | 9 | 2 | 2 | 3 | 1 | 0 | 1 |
| EBITDA | -2 | -4 | -5 | -3 | -2 | -6 | -4 | -3 | -1 | -9 | -1 | -1 | -2 | -1 | 0 | -1 |
| Operating Profit Margin % | -62.00% | -82.00% | -81.00% | -53.00% | -46.00% | -96.00% | -74.00% | -62.00% | 0.00% | 0.00% | 0.00% | 0.00% | -12200.00% | 0.00% | 0.00% | 0.00% |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | -4 | -5 | -7 | -4 | -3 | -7 | -4 | -4 | -1 | -9 | -1 | -1 | -2 | -1 | 0 | -1 |
| Tax | -1 | -1 | -2 | -1 | -1 | -1 | -1 | -1 | -1 | -2 | 0 | 0 | -1 | 0 | 0 | 0 |
| Net Profit | -3 | -5 | -5 | -3 | -2 | -6 | -3 | -3 | -1 | -6 | -1 | -1 | -1 | -1 | 0 | -1 |
| Earnings Per Share (₹) | -0.70 | -1.11 | -1.39 | -0.70 | -0.73 | -2.82 | -0.76 | -0.55 | -0.24 | -4.76 | -0.61 | -0.61 | -0.54 | -0.05 | 0.00 | -0.54 |
PHARMAID Balance Sheet — Assets, Liabilities & Shareholders' Equity
PHARMAID total assets ₹120 Cr, total equity ₹55 Cr, total liabilities ₹ Cr (2025) — ROE -5.5%.
| Particulars | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| Total Assets | 120 | 91 | 25 | 11 |
| Current Assets | 22 | 14 | 18 | 3 |
| Fixed Assets | 77 | 63 | 0 | 0 |
| Capital Work in Progress | 5 | 7 | 2 | 0 |
| Investments | 0 | 0 | 3 | 0 |
| Other Assets | 39 | 21 | 19 | 11 |
| LIABILITIES | ||||
| Total Liabilities | ||||
| Current Liabilities | 36 | 9 | 0 | 0 |
| Non-Current Liabilities | ||||
| SHAREHOLDERS' EQUITY | ||||
| Total Equity | 55 | 71 | 23 | 9 |
| Share Capital | 35 | 35 | 21 | 10 |
| Reserves & Surplus | 24 | 37 | 1 | -2 |
PHARMAID Cash Flow Statement — Operating, Investing & Financing
Pharmaids Pharmaceuticals operating cash flow ₹-14 Cr, investing ₹-12 Cr, financing ₹23 Cr, net cash flow ₹-3 Cr (2025).
| Particulars | March 2025 | March 2024 | March 2023 | March 2022 |
|---|---|---|---|---|
| Operating Activities | -14 | -11 | -4 | 0 |
| Investing Activities | -12 | -75 | -5 | 1 |
| Financing Activities | 23 | 78 | 21 | 0 |
| Net Cash Flow | -3 | -8 | 12 | 0 |